Spectrum Pharma (SPPI) Tops Q1 EPS by 20c; Boosts FY18 Revenue Outlook

Spectrum Pharma (NASDAQ: SPPI) reported Q1 EPS of ($0.15), $0.20 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $0 versus the consensus estimate of $25.68 million.

Financial Guidance

The company has also raised guidance for 2018. Expected 2018 revenue will be between $95 million to $115 million, up from previously projected revenue of $90 million to $110 million. Additionally, the company expects its current cash and marketable securities to be sufficient to fund operations into 2020.

GUIDANCE:

Spectrum Pharma sees FY2018 revenue of $95-115 million, versus the consensus of $105.1 million.

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
• OPENLANE, Inc. (OPLN) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
• Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance